Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib plus abiraterone vs placebo plus abiraterone in first-line metastatic castration-resistant prostate cancer
2018-002011-10Phase 3Unknown
- Sponsor
- AstraZeneca
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olaparib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by AstraZeneca. Status: unknown.
02
Drugs
olaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2018-002011-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002011-10.